Literature DB >> 26617643

EARLY DETECTION AND INTERVENTION FOR PSYCHOSIS: PERSPECTIVES FROM NORTH AMERICA.

Michael T Compton1, Sandra M Goulding1, Claire E Ramsay1, Jean Addington2, Cheryl Corcoran3, Elaine F Walker4.   

Abstract

Clinicians and researchers in Canada and the United States have established a number of early intervention programs and research sites on the early course of psychosis and the prodromal period that commonly precedes psychotic disorders. In Canada, early detection and treatment programs for psychosis have been established in many areas of the country, and typically serve specific catchment areas. Canadian research on early psychosis is often built on to these clinical sites, and covers a broad array of topics including interventions during the prodromal stage of the illness, treatment-seeking behaviors, and development of optimal pharmacological and psychosocial treatment approaches for early psychosis. In the United States, clinical programs for early intervention in psychosis are often located at academic programs with ongoing research on the early course of psychotic disorders. Researchers from sites across the United States offer a plethora of information, including neuroimaging studies, research on treatment response, and the development of standardized rating scales and research instruments. Researchers from sites in both countries have formed a consortium to launch the North American Prodrome Longitudinal Study, a multi-site collaboration to gain a better understanding of the prodromal period of the illness and prediction of conversion from the prodrome to psychosis.

Entities:  

Keywords:  Early detection; Early intervention programs; Prodrome; Psychosis; Schizophrenia

Year:  2008        PMID: 26617643      PMCID: PMC4659432     

Source DB:  PubMed          Journal:  Clin Neuropsychiatry        ISSN: 1724-4935


  66 in total

1.  Mode of onset of psychosis and family involvement in help-seeking as determinants of duration of untreated psychosis.

Authors:  Michael T Compton; Victoria H Chien; Amy S Leiner; Sandra M Goulding; Paul S Weiss
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-05       Impact factor: 4.328

2.  Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up.

Authors:  Peter Milev; Beng-Choon Ho; Stephan Arndt; Peggy Nopoulos; Nancy C Andreasen
Journal:  Biol Psychiatry       Date:  2003-09-15       Impact factor: 13.382

3.  MRI volumetric and 31P MRS metabolic correlates of caudate nucleus in antipsychotic-naïve schizophrenia.

Authors:  P N Jayakumar; G Venkatasubramanian; M S Keshavan; J S Srinivas; B N Gangadhar
Journal:  Acta Psychiatr Scand       Date:  2006-11       Impact factor: 6.392

4.  The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome.

Authors:  Jean Addington; Huma Saeedi; Donald Addington
Journal:  Schizophr Res       Date:  2005-10-01       Impact factor: 4.939

5.  Substance use and cognition in early psychosis.

Authors:  Alissa Pencer; Jean Addington
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

6.  Parahippocampal gyrus in first episode psychotic disorders: a structural magnetic resonance imaging study.

Authors:  Konasale M R Prasad; Brian R Rohm; Matcheri S Keshavan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-07       Impact factor: 5.067

7.  Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

Authors:  Diana O Perkins; Hongbin Gu; Peter J Weiden; Joseph P McEvoy; Robert M Hamer; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2008-01       Impact factor: 4.384

8.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

9.  Early use of clozapine for poorly responding first-episode psychosis.

Authors:  Ofer Agid; Gary Remington; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Journal:  J Clin Psychopharmacol       Date:  2007-08       Impact factor: 3.153

10.  Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

View more
  4 in total

1.  Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP).

Authors:  Beth Broussard; Mary E Kelley; Claire Ramsay Wan; Sarah L Cristofaro; Anthony Crisafio; Patrick J Haggard; Neely L Myers; Thomas Reed; Michael T Compton
Journal:  Schizophr Res       Date:  2013-06-06       Impact factor: 4.939

Review 2.  Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders.

Authors:  Molly K Larson; Elaine F Walker; Michael T Compton
Journal:  Expert Rev Neurother       Date:  2010-08       Impact factor: 4.618

3.  Childhood trauma and children's emerging psychotic symptoms: A genetically sensitive longitudinal cohort study.

Authors:  Louise Arseneault; Mary Cannon; Helen L Fisher; Guilherme Polanczyk; Terrie E Moffitt; Avshalom Caspi
Journal:  Am J Psychiatry       Date:  2010-10-15       Impact factor: 18.112

4.  Implementation of first episode psychosis intervention in India - A case study in a low-and middle-income country.

Authors:  Sridhar Vaitheswaran; Graeme Currie; Vijaya Raghavan Dhandapani; Greeshma Mohan; Thara Rangaswamy; Swaran Preet Singh
Journal:  SSM Ment Health       Date:  2021-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.